Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mydecine Innovations Group ( (TSE:MYCO) ) has provided an announcement.
Mydecine Innovations Group Inc. will change its name to Noveris Health Sciences Inc., with its common shares set to begin trading on the Canadian Securities Exchange under the new ticker symbol “NVRS” on February 2, 2026, while its share capital structure remains unchanged. The rebranding underscores the company’s ongoing evolution within the mental health and psychedelic therapeutics sector, signaling a potential shift in market positioning and corporate identity without altering existing shareholder holdings.
More about Mydecine Innovations Group
Mydecine Innovations Group Inc. is a biotechnology company focused on developing next-generation medications and therapies for mental health disorders, including nicotine addiction and posttraumatic stress disorder (PTSD). Its strategy combines advanced drug discovery technology, a multinational R&D team, and collaborations with leading specialists to create innovative psychedelic-based compounds and therapeutic solutions targeting areas of significant unmet medical need.
Average Trading Volume: 4,136
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$401.4K
See more data about MYCO stock on TipRanks’ Stock Analysis page.